RareResearch.AI
← Back to atlas

K836E

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card
LysineGlutamic acid at position 836 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type K836 — hydrophobic to W678
Fullscreen ↗
DynaMut2 mutant · K836E
Mutant E836 — energy-minimized; 1 new contact formed
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost1 gained1 preserved
Interaction typeWild-type partnerMutant partnerStatus
Polar contactP838Gained
HydrophobicW678W678Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.41kcal/mol
Destabilising — mild
AlphaMissense
0.989
likely pathogenic
AlphaFold pLDDT
82
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Standard confidence · Lumenal

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditionsWolfram-like syndrome
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2506A>G
ClinVar accessionVCV004293166
Last evaluated2025/04/25 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Classified for1★ unverified submission

ClinVar classifies this variant as Uncertain significance for Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are dominant WFS1-related disorders and are clinically distinct from classic recessive Wolfram syndrome. This classification is not a statement about Wolfram syndrome severity.

  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • This rests on a single submitter (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
Absent from gnomAD v4
Homozygotes
Not available

No population breakdown — the variant is absent from gnomAD v4, so no ancestry group has an observed frequency.

No homozygotes — the variant is absent from gnomAD v4 altogether.

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — K836E Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Lysine → Glutamic acid at position 836. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.989, DynaMut2 ΔΔG -0.41 kcal/mol (destabilising).


Identity

FieldValue
VariantK836E (p.Lysine836Glutamic acid)
DNA changec.2506A>G
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV004293166
Amino acid changeLysine (K) → Glutamic acid (E)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 83681.75 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 836 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 836 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is positively charged (lysine — primary amine); the mutant is negatively charged (glutamate — carboxylate). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.9889
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.41 (Destabilising)
Job ID178092089154
Result URLJob 178092089154 · retrieved 2026-06-08 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Uncertain significance — for Wolfram-like syndrome (autosomal dominant, OMIM 614296)

ClinVar classifies this variant as Uncertain significance for Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are dominant WFS1-related disorders and are clinically distinct from classic recessive Wolfram syndrome. This classification is not a statement about Wolfram syndrome severity.

This rests on a single submitter (1★). Treat the conditions above as submitted, not as documented phenotypes. Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2025/04/25 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeK836E is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Wolfram-like syndrome

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.41 < 2 kcal/mol (fold intact) + AlphaMissense 0.989 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.41 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.989. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • K836E_molstar_viewer.html — interactive 3D viewer (auto-highlights position 836 with ball-and-stick + neighbors within 5Å)
  • K836E_variant_card.md — this card (source of truth)
  • K836E_variant_card.html — styled printable card
  • K836E_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • K836E_wildtype_interactions.pse / K836E_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the K836E PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download K836E PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.